Key Developments: Vical Inc (VICL.O)

VICL.O on Nasdaq

27 Mar 2015
Change (% chg)

$0.07 (+7.92%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Vical Inc and AnGes MG announce collaboration to develop therapy for ebola virus disease
Wednesday, 14 Jan 2015 04:59am EST 

Vical Inc and AnGes MG:They have entered into collaboration.To develop and commercialize an equine polyclonal antibody therapy for patients afflicted with Ebola virus disease.No medicines or vaccines are currently approved for treatment of Ebola.  Full Article

Vical Inc granted six U.S. patents for HSV-2 vaccines
Wednesday, 8 Oct 2014 06:30am EDT 

Vical Inc:Announces issuance of six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2 (HSV-2), containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.These patents resulted from collaboration with laboratories of leading HSV experts David Koelle and Lawrence Corey at University of Washington under multi-year NIH grant.Intellectual property is jointly owned by the University of Washington and Vical.  Full Article

Vical Inc announces initiation of phase 1/2 trial of a therapeutic hsv-2 vaccine for genital herpes
Tuesday, 17 Dec 2013 07:00am EST 

Vical Inc:Says the initiation of its Phase 1/2 trial of the company's Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of genital herpes, in about 156 subjects.Says the randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy in otherwise healthy HSV-2- infected patients aged 18 to 50 years at six key U.S. clinical sites.  Full Article

Astellas Pharma Inc's subsidiary and Vical Incorporated announce initiation of phase two trial of ASP0113
Tuesday, 10 Dec 2013 07:00am EST 

Astellas Pharma Inc and Vical Incorporated:Says Astellas Pharma Global Development, Inc., a subsidiary of company and vical initiaties a Phase two trial of ASP0113 in about 140 solid organ transplant (SOT) recipients.The global, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy of ASP0113 compared to placebo as measured by the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor.Says the study will also evaluate the safety of ASP0113 in this patient population.Says follow-up for each subject will continue for one year following enrollment.Says Astellas is conducting the trial under an exclusive worldwide license agreement with Vical to develop and commercialize ASP0113.Says Vical is providing development, regulatory and manufacturing support.  Full Article

Pomerantz Law Firm files class action against vical incorporated
Wednesday, 27 Nov 2013 05:01pm EST 

Vical Inc:Says Pomerantz Grossman Hufford Dahlstrom & Gross LLP files a class action lawsuit against the company and certain of its officers.Says the Complaint alleges that throughout the Class Period, the company made false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects.  Full Article

Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Vical Incorporated
Tuesday, 12 Nov 2013 03:32pm EST 

Glancy Binkow & Goldberg LLP, representing investors of Vical Incorporated announced that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of a class (the "Class") comprising all purchasers of Vical securities between February 8, 2012 and August 9, 2013, inclusive (the "Class Period"). On August 12, 2013, Vical announced the results of the Phase 3 Allovectin trial, which showed that the vaccine failed to show an improvement over chemotherapy, and since "Allovectin simply did not provide the expected benefits," the Allovectin program would be terminated. The Complaint alleges that: The announcement of Allovectin's Phase 3 trial results was deliberately delayed to avoid revealing the truth to the market. Defendants lacked a reasonable basis for their positive statements about the Company and its outlook, including statements about its ability to launch Allovectin.  Full Article

Johnson & Weaver, LLP Files Class Action Suit Against Vical Incorporated
Friday, 1 Nov 2013 11:00am EDT 

Johnson & Weaver, LLP announced that a class action has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Vical Incorporated common stock during the period between February 8, 2012 and August 12, 2013 (the "Class Period"). The complaint alleges that Vical and certain of its officers and/or directors violated the Securities Exchange Act of 1934. Vical is a biopharmaceutical company that researches and develops products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening illnesses, including cancer. All of Vical`s potential products are in the research and development stage, and no revenues have yet been generated from the sale of any products. Vical`s strongest candidate to receive approval by the U.S. Food and Drug Administration for eventual sale and marketing to consumers was Allovectin-7, an immunotherapy vaccine that targets cancer.  Full Article

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Vical Inc
Monday, 12 Aug 2013 02:40pm EDT 

Shareholder rights law firm Johnson & Weaver, LLP announced that it has commenced an investigation into whether certain officers and directors of Vical Inc violated state or federal laws.  Full Article

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Inc
Monday, 12 Aug 2013 12:46pm EDT 

Bronstein, Gewirtz & Grossman, LLC announced that it is investigating potential claims on behalf of purchasers of the securities of Vical Inc (Vical or the Company). The investigation focuses on whether the Company and its executives violated federal securities laws. On August 12, 2013, shares of Vical fell $2.05 or 57% to trade $1.53 during intraday trading after the Company announced it would stop development its drug, Allovectin, after a late-stage trial failed to show that the treatment was significantly better than chemotherapy. According to one analyst who said shareholders would have been better served had the Company analyzed the main and secondary goals separately and ended the trial 12 to 18 months ago, when data showing that the tumors did not shrink was first available.  Full Article

Vical Inc Announces Appointment Of Acting CFO-Form 8-K
Thursday, 18 Apr 2013 02:01pm EDT 

Vical Inc reported in its Form 8-K that as previously reported, Jill M. Broadfoot resigned from her positions as the Company’s Senior Vice President, Chief Financial Officer (CFO) and Secretary effective as of the close of business on April 1, 2013. On April 12, 2013, the Board of Directors appointed Vijay B. Samant, the Company’s President and Chief Executive Officer (CEO), as acting Chief Financial Officer (CFO) while the Company engages in a search for a permanent Chief Financial Officer.  Full Article

Search Stocks